article thumbnail

FDA Issues Guidance on Clinical Pharmacology for Peptide Drugs

PharmaTech

The guidance document discusses the impact of clinical pharmacology considerations on peptide drug development.

article thumbnail

Clinical Pharmacology by ClinicalKey

RX Note

Introduction Clinical Pharmacology powered by ClinicalKey provides current, dependable drug information, including off-label indications, to guide treatment recommendations. Drug Class Overviews Provides information on therapeutic use, comparative efficacy, adverse reactions and drug interactions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

ACMT Toxicology Visual Pearl: The Bark with Some Bite

ALiEM - Pharm Pearls

European Journal of Clinical Pharmacology. European Journal of Clinical Pharmacology. British Journal of Haematology. 2017;177(5):674-683. PMID: 28106908. Schmid B, Kötter I, Heide L. Pharmacokinetics of salicin after oral administration of a standardised willow bark extract. 2001;57(5):387-391. PMID: 11599656.

article thumbnail

Translating complex data into actionable insights, to create big value for smaller biotech companies

BioPharma Dive

Why clinical pharmacology is critical to accelerating drug development, and how it can help drive value in a complex and rapidly evolving landscape.

article thumbnail

Interview: CRO PPD of Thermo Fisher - the processes and difficulties within rare diseases

Outsourcing Pharma

OSP was delighted to speak to Galina Nesterova, executive medical director at the Rare Disease & Pediatrics Center of Excellence, and Susan McCune, vice president of pediatrics and clinical pharmacology both within medical science and strategy at PPD, part of Thermo Fisher.

article thumbnail

WHO INN approves ‘Usnoflast’ as recommended name for ZYIL1 from Zydus

Express Pharma

Zydus was the first to establish the Phase 2 proof-of-concept in Cryopyrin-associated periodic syndromes (CAPS) patients [NCT05186051], and published the Phase 2 results in ‘Clinical Pharmacology in Drug Development’.

article thumbnail

Zydus begins Phase II trial of ZYIL1, NLRP3 inhibitor in patients with ALS

Express Pharma

Zydus has established the Phase 2 proof-of-concept in CAPS patients [NCT05186051] and has now published the data in Clinical Pharmacology in Drug Development. In Phase I studies, ZYIL1 was found to be safe and well-tolerated [NCT04731324, NCT04972188].